HRT Financial LLC acquired a new position in shares of Clorox Co (NYSE:CLX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,541 shares of the company’s stock, valued at approximately $237,000.
A number of other institutional investors have also recently added to or reduced their stakes in CLX. BlackRock Inc. boosted its holdings in Clorox by 7.7% in the fourth quarter. BlackRock Inc. now owns 10,555,837 shares of the company’s stock valued at $1,627,074,000 after acquiring an additional 752,085 shares during the last quarter. Oregon Public Employees Retirement Fund increased its holdings in Clorox by 48,033.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,808,980 shares of the company’s stock worth $44,000 after acquiring an additional 6,794,834 shares during the last quarter. Morgan Stanley increased its holdings in Clorox by 178.2% in the 3rd quarter. Morgan Stanley now owns 3,063,813 shares of the company’s stock worth $460,828,000 after acquiring an additional 1,962,433 shares during the last quarter. Northern Trust Corp increased its holdings in Clorox by 2.8% in the 4th quarter. Northern Trust Corp now owns 2,278,268 shares of the company’s stock worth $351,173,000 after acquiring an additional 61,663 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Clorox by 21.5% in the 4th quarter. Geode Capital Management LLC now owns 1,899,544 shares of the company’s stock worth $292,347,000 after acquiring an additional 335,835 shares during the last quarter. 76.90% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages recently weighed in on CLX. Wells Fargo & Co reissued a “hold” rating and issued a $157.00 price objective on shares of Clorox in a report on Thursday, February 21st. BMO Capital Markets set a $175.00 price objective on Clorox and gave the stock a “buy” rating in a report on Tuesday, February 5th. Zacks Investment Research raised Clorox from a “hold” rating to a “buy” rating and set a $177.00 price objective for the company in a report on Monday, March 11th. Credit Suisse Group began coverage on Clorox in a report on Wednesday, March 6th. They issued an “outperform” rating and a $172.00 price objective for the company. Finally, JPMorgan Chase & Co. lowered Clorox from a “neutral” rating to an “underweight” rating and decreased their price objective for the stock from $159.00 to $139.00 in a report on Monday, April 8th. Five equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $151.21.
Clorox (NYSE:CLX) last issued its quarterly earnings results on Monday, February 4th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.08. The firm had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.47 billion. Clorox had a return on equity of 105.97% and a net margin of 12.65%. The company’s revenue for the quarter was up 4.0% on a year-over-year basis. During the same quarter last year, the company posted $1.77 EPS. Equities research analysts anticipate that Clorox Co will post 6.3 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 10th. Investors of record on Wednesday, April 24th will be issued a dividend of $0.96 per share. The ex-dividend date is Tuesday, April 23rd. This represents a $3.84 dividend on an annualized basis and a dividend yield of 2.49%. Clorox’s dividend payout ratio is 61.34%.
In related news, SVP Andrew J. Mowery sold 5,340 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $156.44, for a total transaction of $835,389.60. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Matthew T. Laszlo sold 10,585 shares of the firm’s stock in a transaction dated Wednesday, February 6th. The shares were sold at an average price of $153.89, for a total value of $1,628,925.65. Following the transaction, the senior vice president now directly owns 17,994 shares in the company, valued at $2,769,096.66. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “HRT Financial LLC Takes Position in Clorox Co (NYSE:CLX)” was first posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/04/24/hrt-financial-llc-invests-237000-in-clorox-co-clx.html.
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.